Type‐2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide

Type‐2 (T2) inflammation is a characteristic feature of asthma. Biological therapies have been developed to target T2‐inflammation in asthma. IL‐13 is a key component of T2‐inflammation in asthma, driving mucus hypersecretion, IgE‐induction, and smooth muscle contraction. Early phase clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Southworth, Thomas, Van Geest, Marleen, Singh, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301554/
https://www.ncbi.nlm.nih.gov/pubmed/34106513
http://dx.doi.org/10.1111/cts.13078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301554/
https://www.ncbi.nlm.nih.gov/pubmed/34106513
http://dx.doi.org/10.1111/cts.13078

Ejemplares similares